Variation in Human Papillomavirus Vaccination Effectiveness in the US by Age at Vaccination
Menée à partir des données d'une enquête américaine portant sur 4 727 filles (âge moyen : 17,9 ans), cette étude compare l'effet, sur la réduction de l'incidence des lésions précancéreuses et du cancer du col de l'utérus, d'une vaccination précoce (entre 9 et 12 ans) et d'une vaccination tardive (après 12 ans) contre le papillomavirus humain, en fonction de l'origine ethnique
The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) recommends routine human papillomavirus (HPV) vaccination at ages 9 to 12 years1 as protection against HPV types 16 and 18 (HPV-16/18), the genotypes in 70% of cervical cancers. Although the importance of vaccination uptake is well known, vaccination often occurs later than recommended. Recent studies have documented the effectiveness of early-age vaccination for reducing cervical precancer and cancer incidence. We used data from the National Health and Nutrition Examination Survey (NHANES)5 to estimate the proportion of female individuals who were vaccinated before sexual debut, assess the association of delayed vaccination with HPV-16/18 prevalence, and quantify potential racial and ethnic disparities in timely vaccination.
JAMA Network Open 2022